# USA, Puerto Rico and US Virgin Islands Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore USA, Puerto Rico and US Virgin Islands HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: USA, Puerto Rico and US Virgin Islands (USA)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $23.9B
- Products: 54
- Buyer markets: 32
- Average CAGR: +11.2%
- Global sector size: $431.4B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $157.4B | $8.2B | $61.4B | +11.1% | 12 | +4.8% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $16.3B | $16.5M | $16.7B | +6.6% | 3 | +0.6% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $53.1B | $6.3B | $16.4B | +17.6% | 7 | +9.3% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $11.1B | $382.2M | $13.7B | +24.6% | 2 | +2.6% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $16.7B | $556.6M | $11.6B | +15.2% | 7 | +3.0% |
| HS 300220 - Vaccines: for human medicine | $14.5B | $1.6B | $11.1B | +20.6% | 4 | +10.7% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $12.6B | $2.6M | $10.8B | +12.0% | 4 | +0.0% |
| HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $6.3B | $16.6M | $10.5B | +6.5% | 4 | +0.3% |
| HS 293379 - Heterocyclic compounds: lactams: other than 6-hexanelactam (epsilon caprolactam) | $8.1B | $138.9M | $9.1B | +14.0% | 3 | +2.4% |
| HS 282200 - Cobalt oxides and hydroxides: commercial cobalt oxides | $4.1B | $17.7K | $7.7B | -10.9% | 2 | +0.0% |
| HS 300339 - Medicaments: containing hormones (excluding insulin), (but not containing antibiotics), for therapeutic or prophylactic uses, not packaged for retail sale | $3.4B | $1.3M | $6.7B | +21.1% | 1 | +0.0% |
| HS 293319 - Heterocyclic compounds: with nitrogen hetero-atom(s) only, containing an unfused pyrazole ring (whether or not hydrogenated) in the structure, other than henazone (antipyrin) and its derivatives | $3.3B | $2.4K | $6.3B | -12.1% | 2 | +0.0% |
| HS 290243 - Cyclic hydrocarbons: p-xylene | $8.5B | $47.7 | $6.3B | -19.2% | 1 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $10.9B | $1.1B | $5.9B | +29.9% | 4 | +7.6% |
| HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $4.1B | $7.9K | $5.9B | -6.8% | 2 | +0.0% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $7.2B | $212.8M | $5.4B | +12.2% | 2 | +2.2% |
| HS 293719 - Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its salts | $2.8B | $147.9M | $4.6B | +39.9% | 2 | +3.5% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $2.8B | $2.0M | $4.6B | +5.0% | 2 | +0.1% |
| HS 281820 - Aluminium oxide: other than artificial corundum | $5.9B | $27.0M | $4.5B | -7.6% | 3 | +0.4% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $3.6B | $228.4M | $4.3B | +8.2% | 2 | +5.7% |
| HS 283691 - Carbonates: lithium carbonate | $2.5B | $45.1K | $3.8B | +1.5% | 1 | +0.0% |
| HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $12.6K | $3.5B | -9.7% | 1 | +0.0% |
| HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $3.8B | $202.8M | $3.4B | +21.0% | 2 | +3.4% |
| HS 310420 - Fertilizers, mineral or chemical: potassic, potassium chloride | $6.9B | $86.2M | $3.2B | +24.8% | 2 | +1.3% |
| HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $4.4B | $945.1M | $3.0B | +39.2% | 1 | +21.6% |
| HS 282520 - Lithium oxide and hydroxide | $1.6B | $40.6M | $2.6B | +12.9% | 1 | +2.5% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $5.6M | $2.3B | +4.5% | 1 | +0.4% |
| HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $17.8M | $2.3B | +14.4% | 1 | +1.4% |
| HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $63.3M | $2.3B | +47.4% | 1 | +3.5% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $9.7B | $992.8M | $2.2B | +23.6% | 1 | +10.2% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $3.3M | $2.1B | -3.7% | 1 | +0.1% |
| HS 284590 - Isotopes (excluding those of heading no. 2844): compounds, inorganic or organic, of such isotopes, whether or not chemically defined | $1.1B | $6.6M | $1.9B | +2.5% | 1 | +0.6% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $4.1M | $1.9B | +16.3% | 1 | +0.3% |
| HS 290122 - Acyclic hydrocarbons: unsaturated, propene (propylene) | $1.6B | $1.7M | $1.8B | +6.5% | 1 | +0.1% |
| HS 310540 - Fertilizers, mineral or chemical: ammonium dihydrogenorthophosphate (monoammonium phosphate) and mixtures thereof with diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $46.4M | $1.7B | +1.8% | 1 | +1.7% |
| HS 284390 - Inorganic or organic compounds: of precious metals (excluding gold and silver), whether or not chemically defined, amalgams of precious metals | $892.9M | $3.3M | $1.7B | +18.5% | 1 | +0.4% |
| HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $456.8M | $1.6B | +11.9% | 1 | +14.1% |
| HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $113.5M | $1.6B | +13.3% | 1 | +5.2% |
| HS 293219 - Heterocyclic compounds: with oxygen hetero-atom(s) only, containing an unfused furan ring (whether or not hydrogenated) in the structure, n.e.c. in item no. 2932.1 | $990.6M | $8.1K | $1.5B | +2.3% | 1 | +0.0% |
| HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $5.9M | $1.4B | -2.6% | 1 | +0.5% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $141.8K | $1.4B | -3.2% | 1 | +0.0% |
| HS 284420 - Uranium: enriched in U235, plutonium, their compounds, alloys dispersions (including cermets), ceramic products and mixtures containing uranium enriched in U235, plutonium or compounds of these products | $1.0B | $2.9K | $1.4B | -6.1% | 1 | +0.0% |
| HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $107.3M | $1.3B | +21.2% | 1 | +7.7% |
| HS 330300 - Perfumes and toilet waters | $1.5B | $16.2M | $1.3B | +12.1% | 1 | +1.1% |
| HS 310530 - Fertilizers, mineral or chemical: diammonium hydrogenorthophosphate (diammonium phosphate) | $2.7B | $237.0 | $1.3B | -37.9% | 1 | +0.0% |
| HS 382370 - Industrial fatty alcohols | $1.0B | $20.8M | $1.2B | +15.4% | 1 | +2.0% |
| HS 310221 - Fertilizers, mineral or chemical: nitrogenous, ammonium sulphate | $965.4M | $11.1M | $1.2B | -2.4% | 1 | +1.1% |
| HS 284330 - Gold compounds | $877.8M | $4.3M | $1.2B | +26.8% | 1 | +0.5% |
| HS 293339 - Heterocyclic compounds: containing an unfused pyridine ring (whether or not hydrogenated) in the structure, other than pyridine and its salts, other than piperidine and its salts | $648.2M | $78.8K | $1.2B | +8.4% | 1 | +0.0% |
| HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $2.0B | $89.9M | $1.2B | +24.0% | 1 | +4.4% |
| HS 380893 - Herbicides, anti-sprouting products and plant-growth regulators: not containing substances of 3808.50: put up in forms or packings for retail sale or as preparations or articles | $2.0B | $410.5M | $1.2B | +7.6% | 1 | +20.9% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $936.5K | $1.1B | +2.8% | 1 | +0.1% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $5.5B | $1.4B | $1.1B | +11.8% | 1 | +24.6% |
| HS 293410 - Heterocyclic compounds: containing an unfused thiazole ring (whether or not hydrogenated) in the structure | $890.3M | $3.5M | $1.1B | +2.5% | 1 | +0.4% |

## Best markets

- China (CHN): $49.9B calculated opportunity across 20 products.
- Slovenia (SVN): $42.9B calculated opportunity across 7 products.
- Switzerland, Liechtenstein (CHE): $32.3B calculated opportunity across 4 products.
- Belgium (BEL): $26.4B calculated opportunity across 6 products.
- Germany (DEU): $23.7B calculated opportunity across 9 products.
- Netherlands (NLD): $14.2B calculated opportunity across 5 products.
- Republic of Korea (KOR): $10.3B calculated opportunity across 5 products.
- Italy (ITA): $9.6B calculated opportunity across 2 products.
- France (FRA): $7.1B calculated opportunity across 4 products.
- Russia (RUS): $6.9B calculated opportunity across 4 products.
- Brazil (BRA): $5.9B calculated opportunity across 4 products.
- United Kingdom (GBR): $5.9B calculated opportunity across 4 products.

## Growth stars

- HS 290121: +47.4% average CAGR, $2.3B calculated opportunity.
- HS 293719: +39.9% average CAGR, $4.6B calculated opportunity.
- HS 300214: +39.2% average CAGR, $3.0B calculated opportunity.
- HS 382499: +29.9% average CAGR, $5.9B calculated opportunity.
- HS 284330: +26.8% average CAGR, $1.2B calculated opportunity.
- HS 310420: +24.8% average CAGR, $3.2B calculated opportunity.
- HS 293359: +24.6% average CAGR, $13.7B calculated opportunity.
- HS 290919: +24.0% average CAGR, $1.2B calculated opportunity.
- HS 330499: +23.6% average CAGR, $2.2B calculated opportunity.
- HS 284690: +21.2% average CAGR, $1.3B calculated opportunity.

## Diversification opportunities

- HS 300490: 12 buyer markets, $61.4B calculated opportunity.
- HS 300215: 7 buyer markets, $16.4B calculated opportunity.
- HS 300439: 7 buyer markets, $11.6B calculated opportunity.
- HS 300220: 4 buyer markets, $11.1B calculated opportunity.
- HS 382600: 4 buyer markets, $10.8B calculated opportunity.
- HS 284190: 4 buyer markets, $10.5B calculated opportunity.
- HS 382499: 4 buyer markets, $5.9B calculated opportunity.
- HS 293399: 3 buyer markets, $16.7B calculated opportunity.
- HS 293379: 3 buyer markets, $9.1B calculated opportunity.
- HS 281820: 3 buyer markets, $4.5B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.